Repository of Research and Investigative Information

Repository of Research and Investigative Information

Hormozgan University of Medical Sciences

Insights into the role of HCV plus-/minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV

(2015) Insights into the role of HCV plus-/minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV. Asian Pacific Journal of Allergy and Immunology.

[img]
Preview
Text
2InsightsAPJAIVol33No3September2015P17.pdf

Download (457kB) | Preview

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background and Objectives: Approximately onethird of hepatitis C virus (HCV) infected patients who complete antiviral therapy with undetectable serum HCV RNA at the end of therapy (ETR), will experience relapse. The reasons for the failure of treatment have not been elucidated. It was showed that HCV RNA can persist and replicate in extra hepatic sites, e.g. in peripheral blood mononuclear cells (PBMCs), but the relevance of its presence with relapse over time is still unknown. Moreover, interferon-gamma (IFN-γ) and IFN-lambdas IFN- λ1, interleukin-29 (IL-29), possess potent antiviral activity. We studied if the presence of plus-/minus strand RNA in PBMCs of patients and the serum level of IFN-γ and IL-29, which is the most abundant IFN-lambdas in serum, can be considered as predictive factors in relapse outcomes. Methods: Patients were screened for plus-/minus strand RNA at ETR and after 6 months. Also, we measured the serum level of IFN-γ and IL-29 and compared the result with those who developed a sustained virological response (SVR). Results: Levels of IL-29 and IFN-γ serum were significantly higher in SVR at ETR and 6 months later compared to those of the relapsed patients, but there was no difference between the two groups regarding the presence or absence of plus-/minus HCV strand in PBMCs. Conclusions: Our novel findings showed that the serum level of IL-29 and IFN-γ are predictive of relapse outcomes to HCV treatment, but there was no association between the presence of plus-/minus HCV RNA in PBMCs of patients with an outcome of therapy at ETR and later. © 2016, Allergy and Immunology Society of Thailand. All right reserved.

Item Type: Article
Additional Information: cited By 2
Keywords: alanine aminotransferase; antivirus agent; complementary DNA; gamma interferon; interleukin 29; virus RNA; biological marker; gamma interferon; IFNG protein, human; IL27 protein, human; interleukin derivative; virus RNA, antiviral activity; antiviral therapy; Article; blood level; clinical article; female; follow up; hepatitis C; Hepatitis C virus subtype 1a; Hepatitis C virus subtype 1b; Hepatitis C virus subtype 3a; human; male; negative-strand RNA virus; peripheral blood mononuclear cell; polymerase chain reaction; positive-strand RNA virus; relapse; treatment outcome; treatment response; virus cell interaction; virus detection; virus load; adult; aged; blood; drug effects; genetics; Hepacivirus; hepatitis C; host pathogen interaction; immunology; middle aged; mononuclear cell; predictive value; recurrent disease; time factor; treatment failure; virology, Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-gamma; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Predictive Value of Tests; Recurrence; RNA, Viral; Time Factors; Treatment Failure
Subjects: WI Digestive System > WI 700-770 Liver. Biliary Tract
Divisions: Research Vice-Chancellor Department > Infectious and Tropical Diseases Research Center
Research Vice-Chancellor Department > Molecular Medicine Research Center
Depositing User: مهندس هدی فهیم پور
URI: http://eprints.hums.ac.ir/id/eprint/4282

Actions (login required)

View Item View Item